References
- Krugman S, McAuliffe VJ, Purcell RH. Hepatitis B vaccines: present status. Semin Liver Dis 1981: 1(1): 81–7
- Blumberg BS, Alter HJ, Visnich S. A “new” antigen in leukemia sera. JAMA 1965: 191(Feb 15): 541–6
- Blumberg BS, Gerstley BJ, Hungerford DA, et al. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967: 66(May): 924–31
- Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970: 1(Apr 4): 695–8
- Hepatitis B vaccine. Med Lett Drugs Ther 1982: 24(Aug 20): 75–8
- Centers for Disease Control. Inactivated hepatitis B virus vaccine. MMWR 1982: 31 (Jun 251: 317–27
- Szmuness W. Stevens CE, Zang EA, et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981: 1(5): 377–85
- Centers for Disease Control. Hepatitis B virus vaccine safety: report of an inter-agency group. MMWR 1982: 31 (Sep 3): 465–7
- Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol 1982: 115 (1): 26–39
- Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis N Engl J Med 1982: 307(11): 644–52